Neurocrine's INGREZZA Shows High Remission Rates In Tardive Dyskinesia Study

Neurocrine Biosciences

120.34 CHF -10.75%

• Charts
• News
• Analysen

Kaufen Verkaufen

(RTTNews) - Neurocrine Biosciences Inc. (NBIX), Thursday unveiled new data at the 2025 Psychiatry Update Conference in Chicago, highlighting the long-term efficacy of INGREZZA or valbenazine in treating tardive dyskinesia.

Tardive dyskinesia is a neurological disorder marked by involuntary, repetitive movements of the face, torso, or other body parts, which can be disruptive and adversely affect patients' quality of life.

Findings from the KINECT 4 study demonstrated that a majority of patients experienced remission after 48 weeks of once-daily treatment.

The post-hoc analysis, based on 103 participants, assessed remission using the Abnormal Involuntary Movement Scale. Results showed that 59.2 percent of patients met the remission threshold, with similar outcomes across both 40 mg and 80 mg doses.

A majority of participants achieved remission regardless of their psychiatric diagnosis or dosage level. Improvements were consistent across psychiatric conditions, reinforcing INGREZZA's effectiveness as a long-term treatment option.

NBIX is currently trading at $110.38, up $0.07 or 0.06 percent on the Nasdaq.